DR. STUART AARONSON, M.D.
Marriage and Family Therapists at 94 St, New York, NY
License number
New York NY109417
Category
Osteopathic Medicine
Type
Family Medicine
Address
Address
40 E 94Th St APT 23B, New York, NY 10128
Phone
(212) 659-5400
(212) 987-2240 (Fax)
(212) 987-2240 (Fax)
Personal information
See more information about STUART AARONSON at radaris.comName
Address
Phone
34 W 75Th St APT 2F, New York, NY 10023
40 E 94Th St APT 23A, New York, NY 10128
70 La Salle St APT 14H, New York, NY 10027
New York, NY
70 La Salle St, New York, NY 10027
Organization information
See more information about STUART AARONSON at bizstanding.comStuart Aaronson MD
40 E 94 St, New York, NY 10128
Industry:
Family Doctor
Stuart Alan Aaronson
Professional information
Chair, Department Of Oncological Sciences At Mount Sinai School Of Medicine
Position:
Chair, Department of Oncological Sciences at Mount Sinai School of Medicine, Chair, Dept. of Oncological Sciences at Mount Sinai School of Medicine, Chair, Dept. of Oncological Sciences at Mount Sinai School of Medicine
Location:
Greater New York City Area
Industry:
Research
Work:
Mount Sinai School of Medicine
-
Chair, Department of Oncological Sciences
Mount Sinai School of Medicine
since 1994
-
Chair, Dept. of Oncological Sciences
Antibodies For The Alpha Platelet-Derived Growth Factor Receptor
US Patent:
6660488, Dec 9, 2003
Filed:
Jan 25, 2001
Appl. No.:
09/769987
Inventors:
Toshimitsu Matsui - Kobe, JP
Stuart A. Aaronson - New York NY
Jacalyn H. Pierce - Pukalani HI
Stuart A. Aaronson - New York NY
Jacalyn H. Pierce - Pukalani HI
Assignee:
The United States of America as represented by the Department of Health Human Services - Washington DC
International Classification:
G01N 3358
US Classification:
435 721, 435 78, 435 697, 435331, 4353441, 436 15, 436512, 436514
Abstract:
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
Epithelial Cell Specific Growth Factor Keratinocyte Growth Factor (Kgf)
US Patent:
2007025, Nov 1, 2007
Filed:
Oct 25, 2006
Appl. No.:
11/585862
Inventors:
Jeffrey Rubin - Potomac MD, US
Paul Finch - Croton-on-Hudson NY, US
Stuart Aaronson - New York NY, US
Paul Finch - Croton-on-Hudson NY, US
Stuart Aaronson - New York NY, US
Assignee:
The Government of U.S.A. as represented by the Secretary, Department of Health and Human Services - Rockville MD
International Classification:
A61K 38/00, A61K 39/00, C07H 21/04, C07K 14/00, C07K 16/00, C12N 15/00, C12N 15/87, C12P 21/04, G01N 33/53
US Classification:
424158100, 435320100, 435325000, 435006000, 435007100, 435070100, 514012000, 530350000, 530389100, 536023500
Abstract:
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
Methods Of Inhibiting The Growth Of Neoplasia Using A Monoclonal Antibody Against .Alpha. Platelet Derived Growth Factor Receptor
US Patent:
5833986, Nov 10, 1998
Filed:
Jun 2, 1995
Appl. No.:
8/460279
Inventors:
William J. LaRochelle - Gaithersburg MD
Jacalyn Pierce - Potomac MD
Roy A. Jensen - Franklin TN
Stuart A. Aaronson - New York NY
Jacalyn Pierce - Potomac MD
Roy A. Jensen - Franklin TN
Stuart A. Aaronson - New York NY
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 39395, C07K 1628, C07K 1622, C07K 1630
US Classification:
4241431
Abstract:
Potent neutralizing monoclonal antibodies to the human. alpha. PDGF receptor (. alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on. alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind. beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing. alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of. alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.
N-Cadherin Modulated Migration, Invasion, And Metastasis
US Patent:
2003005, Mar 20, 2003
Filed:
Feb 22, 2001
Appl. No.:
09/790284
Inventors:
Stuart Aaronson - New York NY, US
Rachel Hazan - New York NY, US
Rachel Hazan - New York NY, US
International Classification:
A61K038/18, G01N033/567
US Classification:
514/012000, 435/007210
Abstract:
The present invention relates to methods for modulating the migratory, invasive and metastatic properties of cells expressing N-cadherin for the treatment of proliferative disorders including, but not limited to, cancers such as melanomas, breast, and prostate cancer. The invention further relates to drug screening assays designed to identify compounds that modulate N-cadherin activity and the use of such compounds in the treatment of disorders involving N-cadherin modulated cell migration, invasion, and metastasis. The invention also relates to methods for diagnosis and prognosis of disorders such as cancer that rely on detection of N-cadherin expression levels. The invention is based on the discovery that N-cadherin expression increases the migratory, invasive and metastatic properties of cells. It is additionally based on the discovery that increased N-cadherin expression sensitizes cells to growth factors such as FGF-2 and increases matrix metalloproteinase-9 (MMP-9) accumulation.
Human Ras-Related Oncogenes Unmasked By Expression Cdna Cloning
US Patent:
5792638, Aug 11, 1998
Filed:
May 24, 1994
Appl. No.:
8/247946
Inventors:
Stuart A. Aaronson - New York NY
Andrew Chan - New York NY
Toru Miki - Rockville MD
Andrew Chan - New York NY
Toru Miki - Rockville MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Rockville MD
and Human Services - Rockville MD
International Classification:
C12N 916, C12N 1501, C12N 1512, C12Q 168
US Classification:
435194
Abstract:
The oncogene of the present invention, isolated by expression cloning from a human ovarian cancer is a mutant of TC21. The present invention teaches that ras-related genes not thought to have transforming potential can contribute importantly to cancers which have been refractory to oncogene detection. The present invention teaches that another ras relative gene, R-ras, which was previously reported to lack transforming potential, has transforming capacity as well. Thus, these and other genes similarly related to prototype and activated by analogous mechanisms may be important in the diagnosis and prognosis of certain cancers, as well as be critical in the design of rational approaches to therapy of cancers in which they play a role.
Epithelial Cell Specific Growth Factor, Keratinocyte Growth Factor (Kgf)
US Patent:
7026291, Apr 11, 2006
Filed:
Jun 7, 1995
Appl. No.:
08/477983
Inventors:
Jeffrey S. Rubin - Potomac MD, US
Paul W. Finch - Croton-on-Hudson NY, US
Stuart A. Aaronson - New York NY, US
Paul W. Finch - Croton-on-Hudson NY, US
Stuart A. Aaronson - New York NY, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/18, C07K 14/475, C07K 14/50
US Classification:
514 12, 514 2, 530350, 530399
Abstract:
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
Immunoassays For The Alpha Platelet-Derived Growth Factor Receptor
US Patent:
6228600, May 8, 2001
Filed:
Jun 2, 1995
Appl. No.:
8/460656
Inventors:
Toshimitsu Matsui - Kita-ku, JP
Stuart A. Aaronson - New York NY
Jacalyn H. Pierce - Pukalani HI
Stuart A. Aaronson - New York NY
Jacalyn H. Pierce - Pukalani HI
Assignee:
The United States of America as represented by the Department of Health and
Human Services - Washington DC
Human Services - Washington DC
International Classification:
G01N 3353, G01N 33577, C07K 1628
US Classification:
435 721
Abstract:
Recombinant DNA technology was used to clone encoding nucleic acids for the human alpha platelet-derived growth factor receptor (PDGF-R type alpha). Peptides corresponding to the predicted sequence of this type and of the PDGF-R type beta were used to elicit antibodies specific for either type of the PDGF-R. Immunoassays are described for determining the level of PDGF-R type alpha in biological samples with the PDGF-R type alpha-specific antibodies.
Epithelial Cell Specific Growth Factor Keratinocyte Growth Factor (Kgf)
US Patent:
2007006, Mar 15, 2007
Filed:
Feb 3, 2006
Appl. No.:
11/346626
Inventors:
Jeffrey Rubin - Potomac MD, US
Paul Finch - Croton-on-Hudson NY, US
Stuart Aaronson - New York NY, US
Paul Finch - Croton-on-Hudson NY, US
Stuart Aaronson - New York NY, US
Assignee:
Department of Health and Human Services - Rockville MD
International Classification:
A61K 38/18, G01N 33/53, C07H 21/04, C12P 21/06, C07K 14/475
US Classification:
514012000, 530399000, 435069100, 435320100, 435325000, 435007100, 536023500
Abstract:
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
Truncated Hepatocyte Growth Factor Variant Protein Hgf/Nk2
US Patent:
7605127, Oct 20, 2009
Filed:
Oct 30, 2002
Appl. No.:
10/283769
Inventors:
Andrew M. L. Chan - Rockville MD, US
Jeffrey S. Rubin - Rockville MD, US
Donald P. Bottaro - Kensington MD, US
Stuart A. Aaronson - New York City NY, US
Stephen J. Stahl - Bethesda MD, US
Paul T. Wingfield - Bethesda MD, US
Vittoria Cioce - New York NY, US
Jeffrey S. Rubin - Rockville MD, US
Donald P. Bottaro - Kensington MD, US
Stuart A. Aaronson - New York City NY, US
Stephen J. Stahl - Bethesda MD, US
Paul T. Wingfield - Bethesda MD, US
Vittoria Cioce - New York NY, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
C07K 14/475, A61K 38/18
US Classification:
514 12, 530399
Abstract:
The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.